Abstract Body

Background

While the US Centers for Disease Control and Prevention recommends dual HIV testing with antigen/antibody (Ag/Ab) and RNA tests during long-acting injectable cabotegravir (CAB-LA) HIV pre-exposure prophylaxis (PrEP), the optimal strategy for monitoring people on CAB-LA for HIV is uncertain.

Methods

Using a microsimulation model, we compare three monitoring strategies for US men who have sex with men and transgender women: dual Ag/Ab and RNA (current recommendations: Ag/Ab+RNA), Ag/Ab-only, and RNA-only at ongoing CAB-LA injection visits. Inputs from HIV Prevention Trials Network 083 and published data include: on-PrEP test sensitivity (Ag/Ab=50%; RNA=75%) and specificity (Ag/Ab=99.84%; RNA=99.91%), HIV incidence (Off PrEP=5.32/100PY; On PrEP=0.26/100PY), and test costs (Ag/Ab=$34; RNA=$93). 10-year outcomes include misdiagnoses (false-positive (FP), false-negative (FN)), quality-adjusted life years (QALYs), HIV-related costs, and incremental cost-effectiveness ratios (ICER=$/QALY; discounted 3%/year). We vary key parameters and pre-PrEP screening strategies in sensitivity analyses.

Results

Ag/Ab+RNA would lead to fewer misdiagnoses (FP=0.0001%, FN=0.0052%) compared with Ag/Ab-only (FP=0.1570%, FN=0.0350%) and RNA-only (FP=0.0884%, FN=0.0120%). However, discordant results (0.2662%) in Ag/Ab+RNA could increase PrEP interruptions. Compared with Ag/Ab+RNA, Ag/Ab-only would decrease costs ($214,400 vs. $218,800) without substantially decreasing QALYs. RNA-only would yield lower costs ($217,300) compared with Ag/Ab+RNA but would yield higher costs compared with Ag/Ab-only and would not be cost-effective (ICER=$49 million/QALY, Fig, Panel A). In sensitivity analyses, RNA-only would be preferred when RNA test cost is ≤$28 across a range of HIV incidences or when both RNA test cost is ≤$46 and Ag/Ab specificity is ≤99.70% (Fig, Panel B). Ag/Ab-only would remain preferred when varying other assumptions, including test sensitivity/specificity, rates of initiating protease inhibitor-based ART following infection on CAB-LA, and PrEP characteristics such as efficacy duration, adherence, and cost. RNA-only would be preferred for pre-PrEP screening when combined with Ag/Ab-only on-PrEP.

Conclusions

For monitoring people on CAB-LA, Ag/Ab-only would be cost-effective compared to current recommendations. Considering pre-PrEP screening, RNA-only pre-PrEP and Ag/Ab-only at CAB-LA injection visits could improve clinical outcomes and be more cost-effective than current recommendations.

Table or Figure